About Index Trending news
Analyze
Pricing
Biogen

Biogen

Employees

Unknown size

Locations
HQ
Xconomy

Biogen, Opening Bottlenecks, Sees Spine Drug Sales, Shares Rise

Health Earnings
BostInno

26 Lawsuits from Biogen | 26 Startups Raised $393M in June

Xconomy

Bristol Flips Remnants of Adnexus, iPierian to Roche, Biogen For $470M

Health
Xconomy

MS Drug Patent Rulings Give Biogen Win, Acorda Loss in Separate Suits

Legal Health
Xconomy

Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins

Health
Xconomy

Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof

Health
Xconomy

Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths

Health Strategy Stock markets
Xconomy

Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval

Health
Xconomy

Biogen to Pay $1.25B to Settle Forward Pharma Patent Suit on MS Drug

Legal
Xconomy

Families Fret As Insurers Mull Biogen's $750K Spine Disease Drug

Health
Xconomy

Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug

Health
Xconomy

Ionis, Biogen Make History With FDA Nod for Spine Disease Drug

Health
Xconomy

New Data Show Biogen, Ionis Drug Might Help More With Rare Spine Disease

Health Science
Xconomy

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More

Health Science
Xconomy

Biogen Buys Ionis Spine Disease Drug For $75M, Eyes FDA Filing

Health
Xconomy

With Biogen at a Crossroads, CEO Scangos to Step Down

Strategy Health Stock markets
The Motley Fool

Better Buy: Biogen Inc. vs. Celgene Corporation

The Motley Fool

Why Biogen Inc. Is Down 22.5% In 2016

The Motley Fool

Is Biogen a Buy After its Clinical Failure?

Health Stock markets
The Motley Fool

Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure

Health